This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
Lung and heart allocation in the United States
American Journal of Transplantation (subscription required)
Share
   
Lung and heart allocation in the United States has evolved over the past 20–30 years to better serve transplant candidates and improve organ utilization. The current lung allocation policy, based on the Lung Allocation Score, attempts to take into account risk of death on the waiting list and chance of survival post-transplant. This policy is flexible and can be adjusted to improve the predictive ability of the score. Here, researchers examine the development of U.S. lung and heart allocation policy, evaluate the application of the current policy on clinical practice and explore future directions for lung and heart allocation.
More
 |
• We are an FDA licensed manufacturer.
• We label peptides, monoclonal antibodies, reagents, chemical and proteins for cancer treatments.
• Our above products can be labeled with radioisotopes such as I-125, I-131, P32, Tc99m, Y90 and AC-225.
• We have a multicurie isotope license and an animal facility.
|
2013 call for committee volunteers
AST
Share
AST offers members the opportunity to contribute their time and expertise through AST committees, advisory councils and communities of practice. Members that are interested in serving on an AST committee or advisory council should submit this online form. As there are only a very small number of open positions on committees and advisory councils this year, we strongly encourage member participation in one or more AST Communities of Practice (COP). COPs are open to everyone, and provide an opportunity to connect with other professionals who share your interests in a specific area. If you would like to participate in a COP, complete this survey and you'll automatically be added to the roster(s) of the COPs selected. The deadline for volunteers is Dec. 21, 2012.
On demand webinars free to AST members
AST
Share
Education when you want it, in less than 60 minutes! Watch webinars in the Timely Topics in Transplantation on demand webinar series: ATC 2012 highlights in infectious disease, live donor kidney outcomes, multi-organ and thoracic transplantation. These webcasts are free to AST members and can be viewed any time, at your leisure. Non-members may view the webcasts for only $25 each. Coming soon: Meeting the challenges of resistance and hepatitis management.
 |
Identify Antibodies That May Compromise Graft Survival
- Detect Presence of Complement Fixing Antibodies
- Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!
FREE SAMPLE
For Research Use Only. Not for use in diagnostic procedures.
|
CEOT: Buy 1 registration, get 1 half off
Share
Register now for the first annual Cutting Edge of Transplantation (CEOT) meeting to take advantage of the buy one registration, get one half off deal. Join the experts to tackle the controversies and challenges related to B cells and antibodies in transplantation, plus attend to abstract presentations and network with others in the field. Learn more about this informative meeting by reading the latest Speaker Spotlight, and then register with your colleagues.
Transplant organizations urge Congress to pass immuno legislation
AST
Share
Earlier this week a letter was distributed to leaders in the House of Representatives and Senate to urge Congress to pass the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients legislation. This letter was signed by major stakeholders in the transplant community. Read the letter.
Business of Transplantation Webinar Series: Live and on demand
AST
Share
Go to a-s-t.org/business to register for the next live webinar in the Business of Transplantation Webinar Series: It's free for AST members and only $50 for non-members. Join Janie Oakley, MSPOD, FACHE and Laura Murdock-Stillion, MHA, FACHE, on Wednesday, Jan. 9 at 2 p.m. EST to learn about transplant regulatory frameworks. Archived versions of the November and December webinars are also available.
Immunosuppression in HCV-positive liver-transplant recipients
Current Opinion in Organ Transplantation (subscription required)
Share
The purpose of this review is to evaluate the historical and recent literature as it pertains to current immunosuppression regimens in hepatitis C virus (HCV)-positive (+) liver-transplant recipients. Recent findings suggest that there are unique differences between HCV transplant recipients and non-HCV transplant recipients, not only in the graft's inflammatory response, but also to the treatments used to prevent and combat rejection.
More
Transumbilical portal venous catheterization: A useful adjunct in left lobe living donor liver transplantation
Clinical Transplantation (subscription required)
Share
To improve the processes used for perfusion of the explanted graft and measuring the portal venous pressure (PVP) in adult living donor transplantation (LDLT), researchers performed transumbilical portal venous catheterization (TPVC) to reopen the umbilical vein and insert the catheter for seven adult patients undergoing left lobe LDLT. There were no major complications as a result of this procedure. This procedure prior to implanting the graft was derived from their experience and is a classic diagnostic technique used during liver surgery. It is a simple and effective procedure for perfusion and washout of the graft and for the safe monitoring of the intraoperative PVP.
More
|
|
|
|
|
 |
|
Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
|
|
|
|
|
 |
|
✓ Hypothermic preservation of a single kidney using physiologic pulsatile preservation and membrane oxygenation: a proven technology from Waters Medical Systems (more than 40 years clinical experience)
✓ Simplifies the perfusion process (provides more options to view, chart, and trend data, offers web-based remote monitoring, and a transportable design)
✓ Meets or exceeds current FDA standards and AOPO and UNOS Preservation Guidelines.
|
|
|
|
|
 |
|
|
When it comes to saving lives, MNX understands organ transplant logistics. Every shipment is urgent, and every step critical. That’s why MNX offers specialty services that are tailored for organ transportation. From expedited ground service to charter flights, MNX has the proven experience and operational resources you can count on.
|
|
Implantable artificial kidney could help tens of thousands: An interview with Shuvo Roy, PhD
Renal & Urology News
Share
With nearly 100,000 patients awaiting a kidney transplant and fewer than one-fifth likely to undergo the procedure each year, a promising hybrid device that works from the inside to provide renal functions beyond dialysis 24 hours a day, seven days a week, has the potential to change a lot of lives, not to mention substantially lower Medicare costs.
More
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data
Liver Transplantation (subscription required)
Share
After liver transplantation (LT), the management of recurrent hepatitis C virus (HCV) infections still remains a major challenge. In HCV genotype 1 patients not undergoing transplantation, the introduction of protease inhibitor (PI)-based regimens has increased the sustained virological response rate significantly. This pilot study investigated both the safety and efficacy of telaprevir (TVR)-based triple therapy in HCV-infected LT patients with a special emphasis on drug-drug interactions between immunosuppressants and PIs.
More
|
|
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact James DeBois at 469-420-2618.
MORE
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Mobile version
A central body fat distribution, as measured by waist-to-hip ratio, is a strong and independent predictor of allograft failure in renal transplant recipients.